The LiFFT Study

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

2 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of the study drug are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing sarcoma. 

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

Eligibility & Criteria

IRB #:
23-020814
Official Title:
Lurbinectedin in FET-Fused Tumors
Study Phase:
Phase I
Phase II
Eligible Age Range:
10 - 99 Years
Gender:
All
Study Categories:

Visit Criteria

As a participant in the research, you will:

  • Receive lurbinectedin (study drug) infusions
  • Complete frequent clinic visits at CHOP Philadelphia
  • Have frequent blood tests, including research blood tests to measure lurbinectedin levels 
  • Have periodic imaging performed to evaluate your response to treatment
  • Have research tumor biopsies with anesthetic agent or general anesthesia (required if you are 18 years or older and your tumor is accessible; optional if you are under 18)
  • Have research genetic tests (if not previously done clinically)
  • Get optional research PET scans with a radioactive tracer
Leader
Patrick J. Grohar

Patrick J. Grohar, MD, PhD